Literature DB >> 24776810

Radioembolization with yttrium-90 microspheres work up: Practical approach and literature review.

G Vesselle1, I Petit2, S Boucebci2, T Rocher2, S Velasco2, J-P Tasu2.   

Abstract

Radioembolization (RE) is a selective internal radiotherapy technique in which yttrium-90 blended microspheres are infused through the hepatic arteries. It is based on the fact that primary and secondary hepatic tumors are vascularized mostly by arterial blood flow whereas healthy hepatocytes obtain their blood supply mostly from the portal network. This enables high radiation doses to be delivered, sparing the surrounding non-malignant liver parenchyma. Most of the complications are caused by unexpected particles passing into the gastrointestinal tract through branches originating from the main hepatic arterial supply. Knowledge of this hepatic arterial network and of its variations and the technical considerations this raises are required in preparation for treatment. This work describes the specific anatomical features and techniques for this anatomy through recent literature illustrated by cases from our own experience.
Copyright © 2014 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Interventional oncology; Radioembolization; Selective internal radiotherapy; Yttrium-90

Mesh:

Substances:

Year:  2014        PMID: 24776810     DOI: 10.1016/j.diii.2014.03.014

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  8 in total

Review 1.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

2.  ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs).

Authors:  Rohini Sharma; Susanna Slater; Joanne Evans; Maria Martinez; Caroline Ward; Hooshang Izadi; Florian Wernig; Rob Thomas
Journal:  BMC Cancer       Date:  2022-07-20       Impact factor: 4.638

Review 3.  MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.

Authors:  Mohanned Alnammi; Jeremy Wortman; Jaclyn Therrien; Jalil Afnan
Journal:  Abdom Radiol (NY)       Date:  2022-05-07

Review 4.  Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.

Authors:  Edward Wolfgang Lee; Lourdes Alanis; Sung-Ki Cho; Sammy Saab
Journal:  Korean J Radiol       Date:  2016-06-27       Impact factor: 3.500

5.  68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies.

Authors:  Elise Verger; Pierre Drion; Geneviève Meffre; Claire Bernard; Luc Duwez; Nicolas Lepareur; Olivier Couturier; François Hindré; Roland Hustinx; Franck Lacoeuille
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

6.  Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study.

Authors:  Arthur J A T Braat; Jip F Prince; Rob van Rooij; Rutger C G Bruijnen; Maurice A A J van den Bosch; Marnix G E H Lam
Journal:  Eur Radiol       Date:  2017-08-07       Impact factor: 5.315

7.  A Woman with Black Beads in Her Stomach: Severe Gastric Ulceration Caused by Yttrium-90 Radioembolization.

Authors:  Indu S Voruganti; James L Godwin; Alyn Adrain; Edward Feller
Journal:  Case Rep Med       Date:  2018-04-15

Review 8.  Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Bela Kis; Ghassan El-Haddad; Rahul A Sheth; Nainesh S Parikh; Suvranu Ganguli; Paul B Shyn; Junsung Choi; Karen T Brown
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.